Zoetis stock reaction and recent performance snapshot

Zoetis (ZTS) has been drawing attention after a sharp pullback, with the stock down about 29% over the past month and 35% over the past 3 months, despite ongoing revenue and net income growth.

At a share price of $79.52, Zoetis has seen short term selling pressure, with the 30 day share price return down 29.3% and the 1 year total shareholder return down 52.1%, suggesting sentiment has cooled despite ongoing revenue and net income growth.

If this kind of sharp move has you looking beyond a single stock, it can be a useful time to broaden your watchlist and check out 40 healthcare AI stocks

With Zoetis shares under pressure despite revenue and net income growth, the key question is whether the current valuation reflects a temporary reset or if the stock still fully prices in future growth potential.

Most Popular Narrative: 14.4% Undervalued

According to a detailed narrative on Zoetis, the fair value is set at $92.92 per share versus the current $79.52, framing the recent sell off as a potential mispricing.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword.

The fair value hinges on steady revenue growth, resilient profit margins, and an earnings profile that leans on disciplined capital returns rather than aggressive expansion. Curious which assumptions sit at the heart of that $92.92 figure and how they stack up against the recent 50% share price decline over 1 year and 54.1% over 5 years.

Result: Fair Value of $92.92 (UNDERVALUED)

However, this hinges on Zoetis managing pressures such as the 11% drop in US Companion Animal revenue and any future impact from generic competition on key products.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly split between concern and optimism, this is a moment to act promptly, review the full picture, and weigh up Zoetis's 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If Zoetis has you rethinking your portfolio, do not stop here. Broaden your opportunity set and let data driven screeners surface ideas you might otherwise miss.

• Target stability with companies that combine quality and resilience by reviewing the 65 resilient stocks with low risk scores.
• Hunt for value by scanning the 46 high quality undervalued stocks that highlights financially strong stocks at potentially appealing prices.
• Spot future standouts early by checking the screener containing 22 high quality undiscovered gems before they hit everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.